PuraPharm Corp. Ltd. is an investment holding company, which engages in the research and development, production and sale of concentrated Chinese medicine granule (CCMG) products and Chinese healthcare products, as well as rendering of Chinese medical diagnostic services. It operates through the following segments: China CCMG, Hong Kong CCMG, Chinese Healthcare Products, Clinics and Plantation. The China CCMG segment manufactures, sells, and researches modernized Chinese medicines in Mainland China. The Hong Kong CCMG segment handles sale of CCMG products excluding the sales through self-operated clinics in Hong Kong. The Chinese Healthcare Products segment consists of operations in Hong Kong, the USA and Japan. The Clinics segment provides Chinese medical diagnostic services. The Plantation segment focuses on the plantation and trading of raw Chinese herbs, and manufacture and sale of TCM decoction pieces. The company was founded by Yu Ling Chan on May 5, 1998 and is headquartered in Hong Kong.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company